JPRN-UMIN000043200Completed未知
Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G) - Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G)
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- West Japan Oncology Group
- Enrollment
- 160
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) History of ramucirumab administration before the start of the secondary treatment 2) If the attending physician or study supervising physician determined the case to be unsuitable
Investigators
Similar Trials
Active, not recruiting
Phase 1
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6
Unknown
Phase 2
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.
Active, not recruiting
Phase 2
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
Active, not recruiting
Phase 1
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyStage IV non-small cell lung cancer (NSCLC)MedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2016-001317-25-ESilly S.A.50
Active, not recruiting
Phase 1
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyEUCTR2016-001317-25-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER50